Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2011

Open Access 01-12-2011 | Primary research

Sensitivity to cisplatin in primary cell lines derived from human glioma correlates with levels of EGR-1 expression

Authors: Antonella Calogero, Antonio Porcellini, Vincenza Lombari, Cinzia Fabbiano, Antonietta Arcella, Massimo Miscusi, Donatella Ponti, Giuseppe Ragona

Published in: Cancer Cell International | Issue 1/2011

Login to get access

Abstract

Background

Less than 30% of malignant gliomas respond to adjuvant chemotherapy. Here, we have asked whether variations in the constitutive expression of early-growth response factor 1 (EGR-1) predicted acute cytotoxicity and clonogenic cell death in vitro, induced by six different chemotherapics.

Materials and methods

Cytotoxicity assays were performed on cells derived from fresh tumor explants of 18 human cases of malignant glioma. In addition to EGR-1, tumor cultures were investigated for genetic alterations and the expression of cancer regulating factors, related to the p53 pathway.

Results

We found that sensitivity to cisplatin correlates significantly with levels of EGR-1 expression in tumors with wild-type p53/INK4a/p16 status.

Conclusion

Increased knowledge of the mechanisms regulating EGR-1 expression in wild-type p53/INK4a/p16 cases of glioma may help in the design of new chemotherapeutic strategies for these tumors.
Appendix
Available only for authorised users
Literature
1.
Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M: Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009, 27: 5743-50. 10.1200/JCO.2009.23.0805.CrossRefPubMed
2.
Ohgaki H, Kleihues P: Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009, 12: 2235-41. 10.1111/j.1349-7006.2009.01308.x.CrossRef
3.
Simon M, Voss D, Park-Simon TW, Mahlberg R, Köster G: Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas. Oncol Rep. 2006, 16: 127-132.PubMed
4.
Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME: MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat Rev Neurol. 2009, 6: 39-51. 10.1038/nrneurol.2009.197.CrossRefPubMed
5.
6.
Makin G, Hickman JA: Apoptosis and cancer chemotherapy. Cell Tissue Res. 2000, 301: 143-52. 10.1007/s004419900160.CrossRefPubMed
7.
Gascoa M, Crook T: p53 family members and chemoresistance in cancer: what we know and what we need to know. Drug Resistance Updates. 2003, 6: 323-328. 10.1016/j.drup.2003.11.001.CrossRef
8.
Gladson CL, Prayson RA, Wei Michael Liu WM: Pathobiology of glioma tumors. Annu Rev Pathol Mech Dis. 2010, 5: 33-50. 10.1146/annurev-pathol-121808-102109.CrossRef
9.
Calogero A, Arcella A, De Gregorio G, Porcellini A, Mercola D, Liu C, Lombari V, Zani M, Giannini G, Gagliardi FM, Caruso R, Gulino A, Frati L, Ragona G: The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. Clin Cancer Res. 2001, 7: 2788-2796.PubMed
10.
Baron V, Adamson ED, Calogero A, Ragona G, Mercola D: The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGF-β1, PTEN, p53, and fibronectin. Cancer Gene Ther. 2006, 13: 115-124. 10.1038/sj.cgt.7700896.PubMedCentralCrossRefPubMed
11.
Ragione FD, Cucciolla V, Criniti V, Indaco S, Borriello A, Zappia V: p21Cip1 gene expression is modulated by Egr-1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect. J Biol Chem. 2003, 278: 23360-23368. 10.1074/jbc.M300771200.CrossRefPubMed
12.
Mittelbronn M, Harter P, Warth A, Lupescu A, Schilbach K, Vollmann H, Capper D, Goeppert B, Frei K, Bertalanffy H, Weller M, Meyermann R, Lang F, Simon P: EGR-1 is regulated by N-methyl-D-aspartate-receptor stimulation and associated with patient survival in human high grade astrocytomas. Brain Pathol. 2009, 19: 195-204. 10.1111/j.1750-3639.2008.00175.x.CrossRefPubMed
13.
Yoshida Y, Nakada M, Sugimoto N, Harada T, Hayashi Y, Kita D, Uchiyama N, Hayashi Y, Yachie A, Takuwa Y, Hamada J: Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. Int J Cancer. 2010, 126: 2341-2352.PubMed
14.
Calogero A, Lombari V, De Gregorio G, Porcellini A, Ucci S, Arcella A, Caruso R, Gagliardi FM, Gulino A, Lanzetta G, Frati L, Mercola D, Ragona G: Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma. Cancer Cell Int. 2004, 7: 1-10.1186/1475-2867-4-1.CrossRef
15.
Krones-Herzig A, Mittal S, Yule K, Liang H, English C, Urcis R, Soni T, Adamson E, Mercola D: Early Growth Response 1 Acts as a Tumor Suppressor In vivo and In vitro via Regulation of p53. Cancer Res. 2005, 65: 5133-5143. 10.1158/0008-5472.CAN-04-3742.CrossRefPubMed
16.
Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V: Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function. Cancer Res. 2004, 64: 8318-8327. 10.1158/0008-5472.CAN-04-1145.CrossRefPubMed
17.
Sangra M, Thorp N, May P, Pizer B, Mallucci C: Management strategies for recurrent ependymoma in the paediatric population. Childs Nerv Syst. 2009, 25: 1283-1291. 10.1007/s00381-009-0914-7.CrossRefPubMed
18.
Park JO, Lopez CA, Gupta VK, Brown CK, Mauceri HJ, Darga TE, Manan A, Hellman S, Posner MC, Kufe DW, Weichselbaum RR: Transcriptional control of viral gene therapy by cis-platin. J Clin Invest. 2002, 110: 403-410.PubMedCentralCrossRefPubMed
19.
Zustovich F, Lombardi G, Della Puppa A, Rotilio A, Scienza R, Pastorelli D: A phase II study of cis-platin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma. Anticancer Res. 2009, 29: 4275-4279.PubMed
20.
Fukushima T, Takeshima H, Kataoka H: Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res. 2009, 29: 4845-4854.PubMed
21.
Nina F, Schor MD: Pharmacotherapy for Adults with Tumors of the Central Nervous System. Pharmacol Ther. 2009, 121: 253-264. 10.1016/j.pharmthera.2008.11.003.CrossRef
22.
Liang BC: Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncology. 1996, 29: 149-155. 10.1007/BF00182138.CrossRef
23.
Lu C, Shervington A: Chemoresistance in gliomas. Mol Cell Biochem. 2008, 312: 71-80. 10.1007/s11010-008-9722-8.CrossRefPubMed
24.
Steinbach JP, Weller M: Apoptosis in gliomas: molecular mechanisms and therapeutic implications. J Neurooncol. 2004, 70: 245-254. 10.1007/s11060-004-2753-4.CrossRefPubMed
25.
Ricevuto E, Ficorella C, Fusco C, Cannita K, Tessitore A, Toniato E, Gabriele A, Frati L, Marchetti P, Gulino A, Martinotti S: Molecular diagnosis of p53 mutations in gastric carcinoma by touch preparation. Am J Pathol. 1996, 148: 405-13.PubMedCentralPubMed
26.
Tatter SB: Recurrent malignamt glioma in adults. Curr Treat Options Oncol. 2002, 3: 509-524. 10.1007/s11864-002-0070-8.CrossRefPubMed
27.
Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC, von Deimling A, Dichgans J: Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int J Cancer. 1998, 79: 640-644. 10.1002/(SICI)1097-0215(19981218)79:6<640::AID-IJC15>3.0.CO;2-Z.CrossRefPubMed
Metadata
Title
Sensitivity to cisplatin in primary cell lines derived from human glioma correlates with levels of EGR-1 expression
Authors
Antonella Calogero
Antonio Porcellini
Vincenza Lombari
Cinzia Fabbiano
Antonietta Arcella
Massimo Miscusi
Donatella Ponti
Giuseppe Ragona
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2011
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-11-5

Other articles of this Issue 1/2011

Cancer Cell International 1/2011 Go to the issue

Primary research

Arsenic, cadmium and neuron specific enolase (ENO2, γ-enolase) expression in breast cancer

Primary research

SKY analysis revealed recurrent numerical and structural chromosome changes in BDII rat endometrial carcinomas

Primary research

Chalcone-imidazolone conjugates induce apoptosis through DNA damage pathway by affecting telomeres

Review

IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors

Review

A short account of metastatic bone disease

Primary research

Cell fusion in tumor progression: the isolation of cell fusion products by physical methods
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits